ROYAL LONDON ASSET MANAGEMENT LTD
Position in HALO — Halozyme Therapeutics, Inc.
CIK 863748
UNITED KINGDOM, X0
Position in HALO
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$141,732,490
+$37,642,450 QoQ
Shares Held
1,810,815
+12.4% QoQ
Ownership
1.60%
of shares outstanding
% of Portfolio
0.26%
of 13F equity value
Holder Rank
#15
of 667 holders
Holding Since
Mar 2025
6 quarters on record
Voting authority
Sole 96%
Shared 0%
None 4%
Common Shares in HALO Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026ROYAL LONDON ASSET MANAGEMENT LTD holds $597,315,774 across 9 Biotechnology names. HALO ranks #2 (23.7% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | RPRX |
Royalty Pharma plc
|
4,319,595 | $242,199,691 | |
| 2 | HALO |
Halozyme Therapeutics, Inc.
This page
|
1,810,815 | $141,732,490 | |
| 3 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
241,280 | $119,851,014 | |
| 4 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
213,589 | $64,296,696 | |
| 5 | INCY |
Incyte Corp
|
190,323 | $21,575,015 | |
| 6 | REGN |
Regeneron Pharmaceuticals, Inc.
|
3,887 | $2,423,699 | |
| 7 | INSM |
INSMED Inc
|
22,116 | $2,358,007 | |
| 8 | LEGN |
Legend Biotech Corp
|
75,000 | $2,166,000 |
All Filings in HALO
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $141,732,490 | 1,810,815 | Shares | Sole | 2026-08-13 | |
| 2026-03-31 | $104,090,040 | 1,610,553 | Shares | Sole | 2026-05-01 | |
| 2025-12-31 | $92,286,538 | 1,371,271 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | $83,846,468 | 1,143,257 | Shares | Sole | 2025-11-13 | |
| 2025-06-30 | $57,321,462 | 1,101,912 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $31,629,085 | 495,676 | Shares | Sole | 2025-05-13 | |
| No filing history on record for this holder in this stock. | ||||||